Physician profile
David C Isbell
NPI 1083652226
$2,382.85
in general payments reported to CMS, 2019-2025
21 companies · $58.07 in 2025
The $58.07 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2021: $21.56 · 2022: $1,017 · 2023: $1,038 · 2024: $14.61 · 2025: $58.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $480.21 | 2019-2024 | |
| Amgen INC. | $312.31 | 2019-2023 | Repatha |
| Medtronic, INC. | $297.24 | 2022 | |
| Pfizer INC. | $224.84 | 2022-2023 | |
| Boston Scientific Corporation | $206.09 | 2022-2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.44 | 2021-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.78 | 2022-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $110.16 | 2022-2023 | Verquvo |
| Alnylam Pharmaceuticals INC. | $101.64 | 2023 | Onpattro |
| Janssen Pharmaceuticals, INC | $85.80 | 2019-2023 | Xarelto |
| Atricure, INC. | $58.07 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| E.R. Squibb & Sons, L.L.C. | $57.51 | 2022 | |
| Cvrx, INC. | $41.99 | 2022 | |
| Scpharmaceuticals INC. | $37.34 | 2023 | |
| Impulse Dynamics (USA) INC. | $26.79 | 2023 | Optimizer |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $19.86 | 2022 | |
| Esperion Therapeutics, INC. | $16.83 | 2022 | |
| Abbott Laboratories | $16.42 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.82 | 2022 | |
| Cashflow Solutions, LLC | $14.16 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Isbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.